1. Home
  2. WIX vs FOLD Comparison

WIX vs FOLD Comparison

Compare WIX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wix.com Ltd.

WIX

Wix.com Ltd.

HOLD

Current Price

$47.96

Market Cap

4.7B

Sector

Technology

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.49

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIX
FOLD
Founded
2006
2002
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.5B
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
WIX
FOLD
Price
$47.96
$14.49
Analyst Decision
Buy
Buy
Analyst Count
22
9
Target Price
$134.67
$27.25
AVG Volume (30 Days)
2.5M
2.5M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.80
$20.50
Revenue Next Year
$13.21
$18.59
P/E Ratio
$28.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$46.90
$5.66
52 Week High
$190.92
$14.50

Technical Indicators

Market Signals
Indicator
WIX
FOLD
Relative Strength Index (RSI) 33.52 74.18
Support Level N/A $14.21
Resistance Level $93.82 N/A
Average True Range (ATR) 3.86 0.02
MACD -0.17 -0.00
Stochastic Oscillator 7.83 100.00

Price Performance

Historical Comparison
WIX
FOLD

About WIX Wix.com Ltd.

Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years it has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: